Literature DB >> 7066598

The effect of gamma-hydroxybutyrate on mouse striatal tyramine, dopamine and homovanillic acid.

A V Juorio.   

Abstract

1 The concentrations of p- and m-tyramine, dopamine and homovanillic acid were measured in the mouse striatum following the subcutaneous injection of gamma-hydroxybutyrate; their control levels were 19.8, 6.3, 9600 and 1130 ng/g respectively. 2 The administration of 500-1000 mg/kg of gamma-hydroxybutyrate produced a reduction in p-tyramine that lasted at least 8 h. m-Tyramine and dopamine were significantly increased for at least 4 h. The levels of homovanillic acid were increased at 1 and 2 h after drug administration. 3 There experiments strongly suggest that the increases in dopamine turnover produced by gamma-hydroxybutyrate caused reciprocal changes in striatal tyramine that are similar to those produced by drug or treatment that increase dopamine turnover and tyrosine hydroxylase activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7066598      PMCID: PMC2071564          DOI: 10.1111/j.1476-5381.1982.tb09160.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  Decrease in homovanillic acid as evidence for dopamine receptor stimulation by apomorphine in the neostriatum of the rat.

Authors:  B E Roos
Journal:  J Pharm Pharmacol       Date:  1969-04       Impact factor: 3.765

2.  Identification and distribution of p-tyramine in the rat.

Authors:  S R Philips; D A Durden; A A Boulton
Journal:  Can J Biochem       Date:  1974-05

3.  Dopaminergic neurons: similar biochemical and histochemical effects of gamma-hydroxybutyrate and acute lesions of the nigro-neostriatal pathway.

Authors:  J R Walters; R H Roth; G K Aghajanian
Journal:  J Pharmacol Exp Ther       Date:  1973-09       Impact factor: 4.030

4.  Enhancement of tyrosine hydroxylation within the brain by chlorpromazine.

Authors:  G Bartholini; A Pletscher
Journal:  Experientia       Date:  1969-09-15

5.  Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra.

Authors:  R L Faull; R Laverty
Journal:  Exp Neurol       Date:  1969-03       Impact factor: 5.330

6.  Conversion of L-tyrosine to 3,4-dihydroxyphenylalanine by cell-free preparations of brain and sympathetically innervated tissues.

Authors:  T Nagatsu; M Levitt; S Udenfriend
Journal:  Biochem Biophys Res Commun       Date:  1964       Impact factor: 3.575

7.  Identification and distribution of m-tyramine in the rat.

Authors:  S R Philips; B A Davis; D A Durden; A A Boulton
Journal:  Can J Biochem       Date:  1975-01

8.  Inhibition by dopamine agonists of dopamine accumulation following gamma-hydroxybutyrate treatment.

Authors:  A Handforth; T L Sourkes
Journal:  Eur J Pharmacol       Date:  1975-12       Impact factor: 4.432

9.  The effect of sodium -hydroxybutyrate on the metabolism of dopamine in the brain.

Authors:  D A Hutchins; K S Rayevsky; D F Sharman
Journal:  Br J Pharmacol       Date:  1972-11       Impact factor: 8.739

10.  Dopaminergic neurons--alteration in the kinetic properties of tyrosine hydroxylase after cessation of impulse flow.

Authors:  V H Morgenroth; J R Walters; R H Roth
Journal:  Biochem Pharmacol       Date:  1976-03-15       Impact factor: 6.100

View more
  4 in total

1.  The effect of raphé nuclei lesions on striatal tyramine concentration and dopamine turnover in the rat.

Authors:  A V Juorio; A J Greenshaw
Journal:  Neurochem Res       Date:  1986-05       Impact factor: 3.996

2.  Cerebral decarboxylation of meta- and para-tyrosine.

Authors:  A A Boulton; A V Juorio
Journal:  Experientia       Date:  1983-02-15

3.  Effects of nutritional stress on brain tyramine concentration and dopamine turnover.

Authors:  S V Bhave; S D Telang; D A Durden; A V Juorio
Journal:  Neurochem Res       Date:  1988-06       Impact factor: 3.996

4.  The effects of amfonelic acid and some other central stimulants on mouse striatal tyramine, dopamine and homovanillic acid.

Authors:  A V Juorio
Journal:  Br J Pharmacol       Date:  1982-11       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.